Traws Pharma Inc (TRAW)

$1.55 +0.02 (1.31%)
Market Cap 7.36M
Revenue (ttm) 230,000.00
Net Income (ttm) -166.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72,400.00%
Debt to Equity Ratio 0.00
Volume 90,000
Avg Vol 85,996
Day's Range N/A - N/A
Shares Out 5.07M
Stochastic %K 15%
Beta 1.43
Analysts Strong Buy
Price Target $6.00

Latest News on TRAW

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 24 days ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 4 weeks ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 4 weeks ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 4 weeks ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 5 weeks ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 7 weeks ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 2 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 3 months ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 3 months ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 4 months ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 4 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 4 months ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 5 months ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 7 months ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 7 months ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 7 months ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 7 months ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 8 months ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 9 months ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 9 months ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 1 year ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 1 year ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 8:18 PM EST - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 1 year ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 1 year ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:08 PM EDT - 1 year ago

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

May 15, 2023, 9:11 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 2 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

May 4, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Mar 23, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Mar 16, 2023, 9:56 PM EDT - 2 years ago

Onconova Therapeutics, Inc. (ONTX) Q4 2022 Earnings Call Transcript

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Mar 16, 2023, 4:04 PM EDT - 2 years ago

Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Mar 9, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Feb 7, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

Dec 19, 2022, 4:05 PM EST - 2 years ago

Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

Dec 7, 2022, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference

Nov 28, 2022, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference